20/20 Biolabs, Inc. Common Stock Cash Flow Reinvestment Rate
20/20 Biolabs, Inc. Common Stock cash flow reinvestment rate. 20/20 Biolabs, Inc. Common Stock (AIDX) has a Cash Flow Reinvestment Rate of 0.05x as of December 2022, reinvesting $261.79K (capex $261.79K ) from operating cash flow of $5.80 Million. Explore AIDX operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of 20/20 Biolabs, Inc. Common Stock (2022–2022)
Cash flow reinvestment rate of 20/20 Biolabs, Inc. Common Stock from 2022 to 2022. Historical reinvestment intensity for 20/20 Biolabs, Inc. Common Stock across 1 annual periods. Explore AIDX capital expenditure intensity to see what proportion of operating cash flow is directed to capital expenditures.
20/20 Biolabs, Inc. Common Stock Cash Flow Reinvestment Rate by Year (2022–2022)
20/20 Biolabs, Inc. Common Stock cash flow reinvestment rate by year from 2022 to 2022. Year-by-year capital reinvestment analysis for 20/20 Biolabs, Inc. Common Stock. For the full cash flow conversion analysis, see 20/20 Biolabs, Inc. Common Stock (AIDX) cash flow conversion.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2022 | 0.05x | $261.79K | $5.80 Million | $261.79K | — |